Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for recurrent implantation failure during frozen embryo transfer
IRCT20221016056198N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Intralipid 10% in Recurrent Implantation Failure (RIF) and female infertility (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Implantation rate, Biochemical pregnancy rate and 2 more. Started Feb 2023; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
Recurrent Implantation Failure (RIF)female infertility
Beyond the preview
Go deeper on IRCT20221016056198N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221016056198N2.